November 11, 2024

Neoadjuvant Therapy Yields Notable Outcomes in Triple-Negative Breast Cancer

The studies summarized here were reported online over the past month in The ASCO Post, generating a high number of visitors. For comprehensive news of these studies and more, visit ASCOPost.com.

The ASCO Post

November 08, 2024

HypoG-01 Trial: Reducing the Treatment Time for Breast Cancer Nodal Irradiation

A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data pr...

The ASCO Post

November 08, 2024

NCCN Guidelines Have Expanded to Meet Growing Understanding of Hereditary Risk

The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to account for the advanced understanding of hereditary cancer risk...

The ASCO Post

November 08, 2024

Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer

In the phase III TULIP trial reported in the Journal of Clinical Oncology, Turner et al found that the third-generation HER2-targeted antibody-drug conjugate trastuzumab duocarmazine improved progress...

The ASCO Post

November 06, 2024

How Hypoxia May Help Cancer Metastasize

Researchers have identified genes that breast cancer cells may use to survive in the bloodstream after escaping the low-oxygen regions of a tumor. 

The ASCO Post

January 12, 2024

Changing Medical Practice Through Translational Research Successes

Converting data and science into medical progress requires a strategic emphasis on work that matters to patients, either through imminent application to clinical practice or potentially transformative basic discoveries.

Cedars-Sinai Pulse

March 13, 2024

Metastatic Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Single-Agent Chemotherapy in Previously Treated Patients

Final results of the phase III ASCENT trial showed continued superior progression-free and overall survival with sacituzumab govitecan-hziy vs physician’s choice of single-agent chemotherapy in previo...

The ASCO Post

October 17, 2023

Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?

Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for ...

The ASCO Post

October 17, 2023

SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression

In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression...

The ASCO Post